Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Ultrasound Outperforms Symptom Analysis In Detecting Ovarian Cancer
Doctors at the University of Kentucky Chandler Medical Center-Markey Cancer Center compared symptom analysis to ultrasound in predicting ovarian cancer. They selected 272 women participating in annual trans-vaginal screening (TVS) from 31,748 women enrolled in a free screening project at the university, comparing symptom results to ultrasound and surgical pathology findings.
generic viagra online
'Hijacking Mechanism' Of HIV-1' Pinpointed By McGill/JGH Researchers
Researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal"s Jewish General Hospital - along with colleagues at the University of Manitoba and the University of British Columbia - may have found a chink in the armour of the human immunodeficiency virus type 1 (HIV-1), the microorganism which causes AIDS. They have pinpointed the key cellular machinery co-opted by HIV-1 to hijack the human cell for its own benefit. Their study was published in May in the Journal of Biological Chemistry.
News of the day
New Data Supports Significant Economic And Clinical Value Of MENOPUR(R) In IVF
New data from an economic analysis presented today at this year"s European Society of Human Reproduction and Embryology (ESHRE) congress showed that, within the parameters of the simulation model used, the in vitro fertilisation (IVF) treatment MENOPUR (highly-purified human menopausal gonatropin or HP-hMG) offered considerable cost-savings over recombinant follicle stimulating hormone (rFSH).1 The cost-effectiveness of HP-hMG compared with rFSH suggested by this data could make it a more attractive choice for use in infertility treatment within a fixed healthcare budget.
Medical Devices

Bosentan Is Cost-Effective For Patients With Moderate PAH

Bosentan appears to be a more cost-effective initial treatment option for patients with moderate pulmonary arterial hypertension (PAH), classified as WHO functional class III, than no active intervention. A cost-utility model was constructed to evaluate the cost-effectiveness of bosentan compared with no active intervention, both added to palliative care in the UK. In the model, simulated patients remained on their initial intervention until death or until they deteriorated to functional class IV, which triggered initiation of intravenous epoprostenol treatment. In the base-case analysis, which assumed that first line treatment did not affect survival, bosentan was more effective and less costly than no active intervention. When survival benefits associated with bosentan treatment were taken into consideration, bosentan was found to be a potential cost effective first line treatment. The work, led by Matt Stevenson was conducted at the University of Sheffield. Dr Stevenson commented: "Long-term follow-up data from randomised controlled trials show that bosentan significantly delays progression to more severe states compared with no active intervention. This results in both potential cost-savings due to a reduction in the duration of relatively expensive epoprostenol treatment and in an improvement in the quality of life for patients." This study is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research and help health care leaders to make decisions that are solidly evidence-based. The journal is published bi-monthly and has a regular readership of over 4,000 clinicians, decision-makers, and researchers worldwide. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care res wisely, fairly, and efficiently. ISPOR


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009